Is CYP1A2 useful for longevity?

The MyBody-X DNA Longevity Test likely includes HLA-DQ2/DQ8 variants, which are strongly associated with celiac disease risk via large GWAS (e.g., PMID 20190752). However, a positive genotype does not equal disease – many carriers never develop celiac. Actionability is moderate: the test can indicate elevated risk, but it cannot diagnose. For a biohacker aiming to optimize longevity, the practical value is limited. Without symptoms or positive serology, adopting a gluten-free diet based solely on genetics lacks evidence and may cause nutrient deficiencies. Moreover, the test’s other longevity markers (e.g., telomere length, methylation) often have weak predictive power. Therefore, HLA-DQ results should be seen as a conversation starter with a physician, not a standalone decision tool. If you have digestive issues, pursue proper medical testing (tTG-IgA, biopsy) rather than relying on a consumer DNA test. In summary: useful for awareness, but not highly actionable for longevity without clinical context.